Novo Nordisk Shares Plunge 23% on Weaker US Sales Growth Outlook
Novo Nordisk’s shares dropped 23% after the company announced its new CEO, Maziar Mike Doustdar, and cut its full-year guidance due to weaker U.S. sales growth forecasts for its weight loss drug Wegovy and diabetes treatment Ozempic. The Danish pharmaceutical giant expects annual operating profit growth of 10-16%, down from a prior target of 16-24%. … Read more